Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Explore this paper's citation graph
Summary
The mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy is identified, pointing to new candidate targets for immune potentiation.
- Type
- article
- Published
- 2015-05-11
- Cited by
- 2,533
- References
- 46
- OpenAlex
- https://openalex.org/W1498931318
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4408057
Keywords
Melanoma, Cancer research, Immunotherapy, Immune system, T cell
References
- CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells
- Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
- β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation
- BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
- Regulated expression of a tumor-associated antigen reveals multiple levels of T cell tolerance in a mouse model of lung cancer
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
- N-myc Downstream-regulated Gene 2, a Novel Estrogen-targeted Gene, Is Involved in the Regulation of Na+/K+-ATPase*
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- Cancer immunotherapy comes of age
- Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
- Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice
- Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
- An integrated map of genetic variation from 1,092 human genomes
- Hedgehog signaling in the neural crest cells regulates the patterning and growth of facial primordia.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Cited by
- Pentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell Populations
- Transcriptional mechanisms of resistance to anti-PD-1 therapy
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- Epigenetic modulation in cancer immunotherapy
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- From Famine to Feast: Developing Early Phase Combination Immunotherapy Trials Wisely
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
- Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
- Patterns of immune cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors
- Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy
- Antigen Presentation in Transplantation
- Excluding T Cells: Is β-Catenin the Full Story?
- The place of PD-1 inhibitors in melanoma management.
- Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance
- Crizotinib: an orphan drug for treating non-small-cell lung cancer
- A dendritic-cell brake on antitumour immunity
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- Melanoma: oncogenic drivers and the immune system.
Related papers
- Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia.
- Wnt Versus Wnt
- 943 Temporal-spatial activation of Wnt-signaling within Type1 / Type 2 immunity during wound healing
- [The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application].
- Advancement of Wnt signal pathway and the target of breast cancer
- New insights into the regulation of Axin function in canonical Wnt signaling pathway
- Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.
- Nkd1 Functions as a Passive Antagonist of Wnt Signaling
- Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy